Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA
November 20 2023 - 2:31PM
Dow Jones News
14:01 EST--Bristol Myers Squibb is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. Shares of Bristol Myers Squibb fell
after the U.S. Food and Drug Administration delayed approval for
Abecma, a blood cancer treatment it developed with 2seventy Bio, to
be used earlier in the treatment process. It is currently approved
for use after four or more prior lines of therapy. Bristol Myers
and 2seventy share all profit and losses for the drug. Dow Jones
& Co. owns Factiva. (matthew.walker@dowjones.com)
(END) Dow Jones Newswires
November 20, 2023 14:16 ET (19:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
2seventy bio (NASDAQ:TSVT)
Historical Stock Chart
From May 2024 to Jun 2024
2seventy bio (NASDAQ:TSVT)
Historical Stock Chart
From Jun 2023 to Jun 2024